Skip to main content

Table 3 Prevalence of comorbidities in patients tested for SARS-CoV-2

From: Outpatient Management of Oligosymptomatic Patients with respiratory infection in the era of SARS-CoV-2: Experience from rural German general practitioners

Tested positive

Tested negative

Diabetes: n = 2 (40.00%)

Diabetes: n = 2 (2.67%)

Arterial hypertension: n = 3 (60.00%)

Arterial hypertension: n = 23 (30.67%)

Hypothyroidism: n = 0 (0%)

Hypothyroidism: n = 11 (14.67%)

Immunosuppression: n = 1 (20.00%)

Immunosuppression: n = 6 (8.00%)

Atrial fibrillation: n = 1 (20.00%)

Atrial fibrillation: n = 5 (6.67%)

Coronary artery disease: n = 0 (0%)

Coronary artery disease: n = 3 (4.00%)

Lung disease: n = 2 (40.00%)

Lung disease: n = 10 (13.33%)

Depression: n = 1 (20.00%)

Depression: n = 11 (14.67%)

Chronic kidney disease: n = 0 (0%)

Chronic kidney disease: n = 2 (2.67%)

RAAS inhibitors: n = 2 (40.00%)

RAAS inhibitors: n = 15 (20.00%)

Oral anticoagulation: n = 1 (20.00%)

Oral anticoagulation: n = 5 (6.67%)

Platelet inhibitors: n = 1 (20.00%)

Platelet inhibitors: n = 1 (1.33%)